MNPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MNPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Monopar Therapeutics's Capital Expenditure for the three months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-3.22 Mil.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
The historical data trend for Monopar Therapeutics's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
Capex-to-Operating-Income | Get a 7-Day Free Trial |
![]() |
- | - | - | - | - |
Monopar Therapeutics Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Capex-to-Operating-Income | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Monopar Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Monopar Therapeutics's Capex-to-Operating-Income falls into.
Monopar Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (0) | / | -16.162 | |
= | N/A |
Monopar Therapeutics's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (0) | / | -3.222 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics (NAS:MNPR) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Thank you for viewing the detailed overview of Monopar Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Tactic Pharma Llc | 10 percent owner | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Andrew Cittadine | officer: Chief Operating Officer | C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091 |
Michael J Brown | director | C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211 |
Arthur J Klausner | director | ONE PALMER SQUARE, PRINCETON NJ 08542 |
Raymond Anderson | director | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Kim R Tsuchimoto | officer: Chief Financial Officer | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Chandler Robinson | director, officer: Chief Executive Officer | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Patrice Rioux | other: Acting Chief Medical Officer | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Christopher M Starr | director | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Filho Jose Octavio Pinto Costa | officer: Chief Medical Officer | C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091 |
Diane Hendricks | 10 percent owner | C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801 |
Karl Leo | 10 percent owner | C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801 |
Kirsten Anderson | officer: SVP, Clinical Development | C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Gem Pharmaceuticals Llc | 10 percent owner | C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Tacticgem Llc | 10 percent owner | 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
From GuruFocus
By GuruFocus News • 11-07-2024
By Marketwired • 09-04-2024
By Marketwired • 11-08-2024
By PRNewswire • 01-23-2025
By GlobeNewswire • 10-29-2024
By Marketwired • 12-05-2024
By GuruFocus News • 10-24-2024
By Marketwired • 10-15-2024
By Marketwired • 10-30-2024
By GuruFocus News • 11-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.